Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.

ABSTRACT:

Introduction

The 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix) was introduced into the Dutch pediatric national immunization program (NIP) starting in 2011. However, there is substantial pneumococcal disease burden due to increases in non-PCV10 covered serotypes. Higher-valent vaccines for pediatrics (PCV13, PCV15, and PCV20) may alleviate much of the remaining disease burden upon implementation through broader serotype coverage. This article assesses the public health impact of different pediatric vaccination strategies (switching to PCV13, PCV15 or PCV20) versus maintaining PCV10 at different time intervals in the Netherlands.

Methods

A population-based, decision-analytic model was developed using historical pneumococcal disease surveillance data to forecast

SUBMITTER: Wilson M 

PROVIDER: S-EPMC10390433 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature